Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
LabGenomics Co's Sloan Ratio for the quarter that ended in Dec. 2024 was -2.38%.
As of Dec. 2024, LabGenomics Co has a Sloan Ratio of -2.38%, indicating the company is in the safe zone and there is no funny business with accruals.
LabGenomics Co Sloan Ratio % Historical Data
The historical data trend for LabGenomics Co's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of LabGenomics Co's Sloan Ratio %
For the Diagnostics & Research subindustry, LabGenomics Co's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LabGenomics Co's Sloan Ratio % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, LabGenomics Co's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where LabGenomics Co's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
LabGenomics Co's Sloan Ratio for the fiscal year that ended in Dec. 2024 is calculated as
LabGenomics Co's Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was -9007.306 (Mar. 2024 ) + 226.221 (Jun. 2024 ) + -2709.471 (Sep. 2024 ) + -12305.423 (Dec. 2024 ) = ₩-23,796 Mil.
LabGenomics Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2024 was -6651.951 (Mar. 2024 ) + -1241.476 (Jun. 2024 ) + -1231.681 (Sep. 2024 ) + -3869.438 (Dec. 2024 ) = ₩-12,995 Mil.
LabGenomics Co's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2024 was -15976.196 (Mar. 2024 ) + 11649.747 (Jun. 2024 ) + -5131.967 (Sep. 2024 ) + 5696.515 (Dec. 2024 ) = ₩-3,762 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LabGenomics Co (XKRX:084650) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Dec. 2024, LabGenomics Co has a Sloan Ratio of -2.38%, indicating the company is in the safe zone and there is no funny business with accruals.
LabGenomics Co Sloan Ratio % Related Terms
Thank you for viewing the detailed overview of LabGenomics Co's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.
LabGenomics Co Ltd is a healthcare company. The Company operates in three business divisions namely NGS, Diagnostic service, IVD products. NGS offers mom guard, cancer panel, Predisposition panel and PGS; Diagnostic service provides esoteric tests such as cancer genetics, genetic disorder. Whereas IVD products include DNA chips, PCR kit among others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:084650 has been successfully added to your 